Program
ziresovir
Also written as “AK0529”, “Ziresovir 125 mg” and “Ziresovir 500 mg”.
Its studies are mostly in Respiratory Syncytial Virus Infections, led by Shanghai Ark Biopharmaceutical.
Furthest: phase 3, since Jan 12, 202012 company-led studies, 1 open or runningNext primary completion: Dec 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Ark Biopharmaceutical | 121 open or running | phase 3since Jan 12, 2020 | Nov 11, 2014 | Dec 2028phase 3 · NCT07658534 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 11, 2014First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT02297594 · 74 enrolled · Australia
- May 27, 2015Phase 1 study in Respiratory Syncytial Virus InfectionsNCT02460016 · 1 enrolled · Australia
- Jan 4, 2016Phase 2 study in Respiratory Syncytial Virus InfectionsNCT02654171 · 72 enrolled · Australia, Hong Kong, Israel and more
- Oct 19, 2017Phase 1 study in HealthyNCT03322800 · 51 enrolled · China
- Jan 10, 2018Phase 1 study in HealthyNCT03400995 · 7 enrolled · United Kingdom
- Oct 5, 2018Phase 2 study in Respiratory Syncytial Virus InfectionsNCT03699202 · 1 enrolled · China
- Jan 12, 2020Phase 3 study in Respiratory Syncytial Virus InfectionsNCT04231968 · 311 enrolled · China
- Feb 1, 2021Phase 1 study in Healthy SubjectsNCT04788017 · 24 enrolled · United States
- Mar 24, 2023Phase 2 study in Respiratory Syncytial Virus InfectionsNCT06942299 · 25 enrolled · China
- Sep 4, 2024Phase 1 study in Healthy VolunteersNCT06591845 · 34 enrolled · United States
- Dec 16, 2024Phase 3 study in Respiratory Synctial Virus InfectionsNCT06775405 · 180 enrolled · China
- Mar 30, 2026Phase 3 study in Respiratory Syncytial Virus InfectionsNCT07658534 · 290 planned · China
Ahead
- Dec 2028Primary completion: phase 3 study in Respiratory Syncytial Virus InfectionsNCT07658534
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Fusion glycoprotein F0 inhibitor”ChEMBL 37, by rule
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07658534Respiratory Syncytial Virus Infections · China | 3 | Recruiting | Dec 2028 | 290 |
| NCT06775405Respiratory Synctial Virus Infections · China | 3 | Completed | Apr 7, 2025 | 180 |
| NCT06591845Healthy Volunteers · United States | 1 | Completed | Dec 16, 2024 | 34 |
| NCT06942299Respiratory Syncytial Virus Infections · China | 2 | Completed | Jun 28, 2024 | 25 |
| NCT04788017Healthy Subjects · United States | 1 | Completed | Jun 14, 2021 | 24 |
| NCT04231968Respiratory Syncytial Virus Infections · China | 3 | Completed | Jan 21, 2022 | 311 |
| NCT03699202Respiratory Syncytial Virus Infections · China | 2 | Terminated | Apr 4, 2019 | 1 |
| NCT03400995Healthy · United Kingdom | 1 | Completed | Feb 27, 2018 | 7 |
| NCT03322800Healthy · China | 1 | Completed | Apr 6, 2018 | 51 |
| NCT02654171Respiratory Syncytial Virus Infections · Australia, Hong Kong, Israel and more | 2 | Completed | Mar 31, 2019 | 72 |
| NCT02460016Respiratory Syncytial Virus Infections · Australia | 1 | Terminated | Nov 3, 2015 | 1 |
| NCT02297594Respiratory Syncytial Virus Infections · Australia | 1 | Completed | Jun 2015 | 74 |
How it is read
Names in the registry
- “AK0529”, 10 entries
- “Ziresovir 125 mg”, 1 entry
- “Ziresovir 500 mg”, 1 entry
- “Ziresovir (AK0529)”, 1 entry
- “Ziresovir”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Syncytial Virus Infections, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.